DNA methylation profiling in inflammatory bowel disease provides new insights into disease pathogenesis.

Inflammatory Bowel Diseases (IBDs) are heterogeneous disorders with complex aetiology. Quantitative genetic studies suggest that only a small proportion of the disease variance observed in IBD is accounted for by genetic variation, indicating a potential role for differential epigenetic regulation in disease aetiology. The aim of this study was to assess genome-wide DNA methylation changes specifically associated with Ulcerative Colitis (UC), Crohn's Disease (CD) and IBD activity. DNA methylation was quantified in peripheral blood mononuclear cells (PBMCs) from 149 IBD cases (61 UC, 88 CD) and 39 controls using the Infinium HumanMethylation450 BeadChip. Technical and functional validation was performed using pyrosequencing and real-time PCR. Cross-tissue replication of the top differentially methylated probes (DMPs) was tested in colonic mucosa tissue samples obtained from paediatric IBD cases and controls. A total of 3,196 probes were differentially methylated between CD cases and controls, while 1,481 probes were differentially methylated between UC cases and controls. There was considerable (45%) overlap between UC and CD DMPs. The top-ranked IBD-associated PBMC differentially methylated region (promoter region of TRIM39-RPP2) was also significantly hypomethylated in colonic mucosa from paediatric UC patients. In addition, we confirmed TRAF6 hypermethylation using pyrosequencing and found reduced TRAF6 gene expression in PBMCs of IBD patients. Our data provide new insights into differential epigenetic regulation of genes and molecular pathways, which may contribute to the pathogenesis and activity of IBD.AbbVieBoston Scientific Newman Fellowship, awarded by the UCD FoundationGutsy Kids FundKaren and Brock Wagner familyHouston Men of DistinctionNational Institutes of Healt